Answers are grounded in this paper and cite their sources.
This study reports improved follicle counts and AMH levels in rats with ovarian injury, suggesting mangiferin may mitigate ischemic damage.
Objective: Ischemia-reperfusion (IR) injury in the ovary can cause significant structural damage and compromise ovarian reserve by disrupting follicular integrity. This study aimed to investigate the protective effects of Mangiferin, a natural antioxidant and anti-inflammatory compound, in a rat model of ovarian IR injury. Histopathological evaluation, follicle counts, and serum anti-Müllerian hormone (AMH) levels were used to assess treatment efficacy. Methods: Thirty-two female Sprague-Dawley rats were divided into Control, Mangiferin, IR, and IR+ Mangiferin. Ovarian IR was induced by bilateral clamping of the ovarian vasculature for 3 hours, followed by 3 hours of reperfusion. Mangiferin (20 mg/kg) was administered intraperitoneally once daily for 15 days. Ovarian tissues were subjected to histological analysis with follicle counts and AMH levels were measured using ELISA. Results: The IR group exhibited marked histopathological changes, including vascular congestion, hemorrhage, edema, inflammatory cell infiltration, and extensive follicular degeneration. In contrast, the IR+ Mangiferin group showed improved tissue architecture, higher follicle counts, and AMH levels that were significantly preserved compared to the IR group. Conclusion: Mangiferin may reduce ovarian damage caused by IR injury and contribute to the preservation of ovarian reserve. These findings suggest a potential therapeutic benefit of Mangiferin in protecting ovarian tissue under ischemic conditions.
No takes yet. Share an insight, caveat, or question.
Ayaz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: